Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.
Completed
- Conditions
- Polycystic Ovary Syndrome
- Registration Number
- NCT01644305
- Lead Sponsor
- Ankara Education and Research Hospital
- Brief Summary
The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 85
Inclusion Criteria
- Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism
Exclusion Criteria
- acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs.
any medication known to affect hormonal or metabolic parameters.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome 1 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link GDF-9 and GDF-15 to bone density changes in Polycystic Ovary Syndrome (PCOS)?
How do plasma GDF-15 levels correlate with insulin resistance markers in PCOS patients aged 25-35?
Are GDF-9 or GDF-15 potential biomarkers for cardiovascular risk stratification in PCOS populations?
What comparative evidence exists for GDF-15 as a therapeutic target versus traditional hormonal treatments in PCOS?
How might GDF-15 modulation synergize with aromatase inhibitors in addressing metabolic dysregulation in PCOS?
Trial Locations
- Locations (1)
Ankara Education and Research Hospital
🇹🇷Ankara, Turkey
Ankara Education and Research Hospital🇹🇷Ankara, Turkey